b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30561189</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>07</Month>\n            <Day>30</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>07</Month>\n            <Day>30</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1944-8252</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>11</Volume>\n                    <Issue>2</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Jan</Month>\n                        <Day>16</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>ACS applied materials &amp; interfaces</Title>\n                <ISOAbbreviation>ACS Appl Mater Interfaces</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Metal-Organic Frameworks as Drug Delivery Platforms for Ocular Therapeutics.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1924-1931</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1021/acsami.8b20222</ELocationID>\n            <Abstract>\n                <AbstractText>Metal-organic frameworks (MOFs) have been evaluated as potential nanocarriers for intraocular incorporation of brimonidine tartrate to treat chronic glaucoma. Experimental results show that UiO-67 and MIL-100 (Fe) exhibit the highest loading capacity with values up to 50-60 wt %, whereas the performance is quite limited for MOFs with narrow cavities (below 0.8 nm, for example, UiO-66 and HKUST-1). The large loading capacity in UiO-67 is accompanied by an irreversible structural amorphization in aqueous and physiological media that promotes extended release kinetics above 12 days. Compared to the traditional drawbacks associated with the sudden release of the commercial drugs (e.g., ALPHAGAN), these results anticipate UiO-67 as a potential nanocarrier for drug delivery in intraocular therapeutics. These promising results are further supported by cytotoxicity tests using retinal photoreceptor cells (661W). Toxicity of these structures (including the metal nodes and organic ligands) for retinal cells is rather low for all samples evaluated, except for HKUST-1.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Gandara-Loe</LastName>\n                    <ForeName>Jes\xc3\xbas</ForeName>\n                    <Initials>J</Initials>\n                    <Identifier Source="ORCID">http://orcid.org/0000-0003-1334-4788</Identifier>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ortu\xc3\xb1o-Lizar\xc3\xa1n</LastName>\n                    <ForeName>Isabel</ForeName>\n                    <Initials>I</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Fern\xc3\xa1ndez-Sanchez</LastName>\n                    <ForeName>Laura</ForeName>\n                    <Initials>L</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ali\xc3\xb3</LastName>\n                    <ForeName>Jorge L</ForeName>\n                    <Initials>JL</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Research and Development Department , VISSUM Corporation , E-03016 Alicante , Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Cuenca</LastName>\n                    <ForeName>Nicol\xc3\xa1s</ForeName>\n                    <Initials>N</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Vega-Estrada</LastName>\n                    <ForeName>Alfredo</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Research and Development Department , VISSUM Corporation , E-03016 Alicante , Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Silvestre-Albero</LastName>\n                    <ForeName>Joaqu\xc3\xadn</ForeName>\n                    <Initials>J</Initials>\n                    <Identifier Source="ORCID">http://orcid.org/0000-0002-0303-0817</Identifier>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>01</Month>\n                <Day>02</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>ACS Appl Mater Interfaces</MedlineTA>\n            <NlmUniqueID>101504991</NlmUniqueID>\n            <ISSNLinking>1944-8244</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000073396">Metal-Organic Frameworks</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D009942">Organometallic Compounds</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C539834">bis(1,3,5-benzenetricarboxylate)tricopper(II)</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>4S9CL2DY2H</RegistryNumber>\n                <NameOfSubstance UI="D000068438">Brimonidine Tartrate</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000068438" MajorTopicYN="Y">Brimonidine Tartrate</DescriptorName>\n                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004337" MajorTopicYN="Y">Drug Carriers</DescriptorName>\n                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005123" MajorTopicYN="N">Eye</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005128" MajorTopicYN="N">Eye Diseases</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000073396" MajorTopicYN="Y">Metal-Organic Frameworks</DescriptorName>\n                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009942" MajorTopicYN="Y">Organometallic Compounds</DescriptorName>\n                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">MOFs</Keyword>\n            <Keyword MajorTopicYN="N">amorphization</Keyword>\n            <Keyword MajorTopicYN="N">drug delivery</Keyword>\n            <Keyword MajorTopicYN="N">glaucoma treatment</Keyword>\n            <Keyword MajorTopicYN="N">ocular therapeutics</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>12</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>31</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>12</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30561189</ArticleId>\n            <ArticleId IdType="doi">10.1021/acsami.8b20222</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'